TEPEZZA Market Summary
Key Factors Driving TEPEZZA Growth
• First-and-only approved therapy for Thyroid Eye Disease (TED)
TEPEZZA remains the first and only FDA-approved therapy specifically indicated for TED, including both active and chronic disease. Since its approval in 2020, it has fundamentally changed TED management by targeting insulin-like growth factor-1 receptor (IGF-1R), a root cause of the disease rather than simply treating symptoms. Multiple clinical studies demonstrated significant reductions in proptosis (eye bulging) and diplopia (double vision), two hallmark TED manifestations.
• Strong commercial performance and sustained patient demand
TEPEZZA has remained a major rare-disease revenue driver for Amgen. In Q4 2025, TEPEZZA generated US$457 million in quarterly sales, while full-year sales increased 3% year-over-year despite temporary inventory fluctuations. Amgen also reported continued volume growth, reflecting sustained physician adoption and demand expansion. Since launch, more than 25,000 patients worldwide have received TEPEZZA treatment.
• Subcutaneous formulation could significantly expand market penetration
In April 2026, Amgen announced positive Phase III results for a subcutaneous on-body injector (OBI) formulation of TEPEZZA. The study demonstrated a highly significant 77% proptosis responder rate with clinically meaningful reductions exceeding 3 mm. A subcutaneous option could substantially improve patient convenience compared with the current intravenous infusion regimen, reduce infusion-center burden, and increase accessibility. This lifecycle expansion may help sustain TEPEZZA’s competitive position as rival TED therapies enter development.
• Global expansion opportunities remain underpenetrated
TEPEZZA received approval in Japan in 2024, becoming the first approved TED therapy in Asia. Amgen estimated approximately 25,000–35,000 TED patients in Japan alone, including active and chronic disease populations. Ongoing expansion into additional international markets could materially increase the addressable patient base and diversify revenue beyond the United States.
• High unmet need and chronic disease burden support long-term demand
TED is a progressive autoimmune disease that can cause vision-threatening complications, facial disfigurement, pain, and significant quality-of-life impairment. Many patients historically relied on corticosteroids, surgery, or radiation with limited efficacy. Real-world patient discussions and clinical experience continue to highlight substantial symptomatic improvements with TEPEZZA, particularly in eye bulging, pain, and pressure symptoms. This strong clinical differentiation supports ongoing physician preference despite concerns around adverse events such as hearing impairment and hyperglycemia.
TEPEZZA Recent Developments
• In April 2026, Amgen announced positive topline results from a Phase III trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED). TEPEZZA OBI provides comparable efficacy to, and builds upon the success of, intravenous (IV) TEPEZZA, the first and only medicine approved for the treatment of TED, which has now treated more than 25,000 patients worldwide.
“TEPEZZA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of TEPEZZA for approved indication like Graves ophthalmopathy in the 7MM. A detailed picture of TEPEZZA’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the TEPEZZA for approved indications. The TEPEZZA market report provides insights about TEPEZZA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current TEPEZZA performance, future market assessments inclusive of the TEPEZZA market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of TEPEZZA sales forecasts, along with factors driving its market.
TEPEZZA Drug Summary
TEPEZZA is a fully human monoclonal antibody developed by Amgen and originally by Horizon Therapeutics for the treatment of thyroid eye disease (TED), a rare and debilitating autoimmune condition associated with Graves’ disease. Administered as an intravenous infusion, TEPEZZA specifically targets and inhibits the insulin-like growth factor-1 receptor (IGF-1R), which is overexpressed in orbital fibroblasts and immune cells involved in TED pathogenesis. By blocking IGF-1R signaling, the drug reduces inflammation, tissue expansion, fibrosis, and proptosis (eye bulging), thereby improving vision-related symptoms, diplopia, pain, and quality of life. TEPEZZA became the first FDA-approved therapy for TED in 2020 after pivotal Phase III OPTIC studies demonstrated significant reductions in proptosis and clinical activity scores compared with placebo. The therapy has shown durable responses in both active and chronic TED, although adverse events such as muscle spasms, hearing impairment, hyperglycemia, and infusion reactions have been reported. TEPEZZA’s targeted mechanism and strong clinical efficacy have established it as a transformative therapy in the management of thyroid eye disease. The report provides TEPEZZA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the TEPEZZA Market Report
The report provides insights into:
• A comprehensive product overview including the TEPEZZA MoA, description, dosage and administration, research and development activities in approved indication like Graves ophthalmopathy.
• Elaborated details on TEPEZZA regulatory milestones and other development activities have been provided in TEPEZZA market report.
• The report also highlights TEPEZZA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The TEPEZZA market report also covers the patents information, generic entry and impact on cost cut.
• The TEPEZZA market report contains current and forecasted TEPEZZA sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The TEPEZZA market report also features the SWOT analysis with analyst views for TEPEZZA in approved indications.
Methodology
The TEPEZZA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
TEPEZZA Analytical Perspective by DelveInsight
• In-depth TEPEZZA Market Assessment
This TEPEZZA sales market forecast report provides a detailed market assessment of TEPEZZA for approved indication like Graves ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted TEPEZZA sales data uptil 2034.
• TEPEZZA Clinical Assessment
The TEPEZZA market report provides the clinical trials information of TEPEZZA for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
TEPEZZA Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
TEPEZZA Market Potential & Revenue Forecast
• Projected market size for the TEPEZZA and its key indications
• Estimated TEPEZZA sales potential (TEPEZZA peak sales forecasts)
• TEPEZZA Pricing strategies and reimbursement landscape
TEPEZZA Competitive Intelligence
• Number of competing drugs in development (pipeline analysis)
• TEPEZZA Market positioning compared to existing treatments
• TEPEZZA Strengths & weaknesses relative to competitors
TEPEZZA Regulatory & Commercial Milestones
• TEPEZZA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity
TEPEZZA Clinical Differentiation
• TEPEZZA Efficacy & safety advantages over existing drugs
• TEPEZZA Unique selling points
TEPEZZA Market Report Highlights
• In the coming years, the TEPEZZA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The TEPEZZA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TEPEZZA’s dominance.
• Other emerging products for Graves ophthalmopathy are expected to give tough market competition to TEPEZZA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TEPEZZA in approved indications.
• Analyse TEPEZZA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted TEPEZZA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of TEPEZZA in approved indications.
Key Questions
• What is the class of therapy, route of administration and mechanism of action of TEPEZZA? How strong is TEPEZZA’s clinical and commercial performance?
• What is TEPEZZA’s clinical trial status in each individual indications such as Graves ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TEPEZZA Manufacturers?
• What are the key designations that have been granted to TEPEZZA for approved indications? How are they going to impact TEPEZZA’s penetration in various geographies?
• What is the current and forecasted TEPEZZA market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of TEPEZZA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to TEPEZZA for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is TEPEZZA? What is the duration of therapy and what are the geographical variations in cost per patient?
